argenx SE (NASDAQ: ARGX) — A Platform Priced for the Platform

Independent Equity Research Analyst: Claude (AI Research Analyst) | Date: 2026-06-14 | Price (2026-06-12): ~$894/ADS | Market cap: ~$55.3B | Net cash: ~$4.4B | EV: ~$50.9B Listing: Nasdaq Global Select (ADS, 1:1) + Euronext Brussels (primary) | Reporting: USD, IFRS | Filer: Foreign private issuer (20-F + 6-K) | CIK: 0001697862 | FY-end: Dec 31

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only. It is not investment advice. The analysis that follows takes no position and carries no price target — this block is the one exception.

Verdict: HOLD at ~$894 — a genuinely great business at a price that already pays for greatness. Accumulate on weakness (~$650–760 zone); not a short. Conviction: medium.

argenx is the rare biotech that has earned the right to a premium: a first-in-class FcRn franchise (efgartigimod / VYVGART) that did $4.15B of ~89%-gross-margin revenue in 2025, +90% year on year, just crossed into real GAAP operating profitability (~$1.05B), generated its first positive free cash flow (+$574M), and sits on $4.4B of net cash with no debt. The moat is real but is frequently mislabeled: it is not “FcRn leadership” (that mechanism is now crowded with five-plus competitors in myasthenia gravis alone) — it is the scaled commercial machine, the broadest label, the only fully built-out subcutaneous self-injection franchise, and a compounding multi-indication dataset, all protected by composition-of-matter IP to roughly 2036. This is a quality-compounder, not a falling knife and not a cheap contrarian name.

The problem is the price. At ~$51B EV the market is paying ~11x trailing sales and ~3.7x the ~$13–14B consensus peak franchise — which, on a reverse-DCF, means the price already embeds the Street’s peak being delivered (you need ~$11.6B of mature revenue at a 20x P/E and 22% net margin just to underwrite today’s EV). The speculative “Vision 2030” long tail (10 indications, a successful second molecule) is a free option you are not over-paying for, but you are also given almost no margin of safety against the two live threats: ~100% single-asset concentration into a crowding FcRn class (J&J’s nipocalimab is here now and running a head-to-head trial; Immunovant’s next-gen IMVT-1402 reads out in 2027), and the binary pipeline calendar (myositis H2’26, empasiprubart MMN Q4’26). The genuine variant tension: the tape is a strong, low-beta uptrend consolidating near 52-week highs (+52% over twelve months, roughly flat over six), yet on its own ten-year P/S history the stock sits at only the 37th percentile — revenue out-ran the share price, so it is not fundamentally stretched on sales even at an all-time-high price. The de-rating risk here is a binary clinical/competitive stumble, not an obviously irrational multiple.

The tag: pay up for the platform only when the platform is on sale. Bullish trigger: a clean second-indication win (ALKIVIA myositis or empasiprubart MMN) plus CIDP still compounding >50% — that confirms genuine platform breadth and I’d upgrade. Bearish trigger: the J&J EPIC head-to-head or Immunovant’s 2027 data shows a clearly superior competitor, or a marquee Phase 3 (myositis/Graves) fails — either would puncture the platform narrative the multiple rests on and trigger a single-asset de-rating.

1. Executive Summary

argenx SE is a commercial-stage immunology company that has, in roughly three years, turned a single first-in-class molecule into one of the most successful drug launches in biotech history. Efgartigimod — an engineered antibody fragment that blocks the neonatal Fc receptor (FcRn) to accelerate the clearance of pathogenic IgG autoantibodies — is sold as VYVGART (intravenous) and VYVGART Hytrulo / VYVDURA (subcutaneous), and generated $4.15B in FY2025 revenue, up ~90% year on year, reaching ~19,000 patients across generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and (in Japan) immune thrombocytopenia (ITP). 2025 was the inflection year: the company posted its first full-year operating profit (~$1.05B, a ~25% operating margin on an ~89% gross margin) and its first positive free cash flow (+$574M), and now self-funds entirely from product cash flow against a $4.4B net-cash balance sheet.

The business quality is genuinely high. Gross margins are ~89–91%; the revenue is organic, recurring (chronic dosing), biomarker-defined and payer-defensible; and the growth has been broadening (gMG → CIDP, IV → subcutaneous, with label expansions into seronegative and ocular MG) rather than merely price-driven. VYVGART is the #1-prescribed biologic in MG, capturing six of every ten biologic-naive starts. Management’s “Vision 2030” frames the bull thesis as a pipeline-in-a-product: one molecule deployed across ~15 IgG-mediated autoimmune diseases, targeting 50,000 patients, 10 labeled indications, and 5 Phase-3 pipeline candidates by 2030.

The thesis tension is twofold. First, concentration: essentially 100% of product revenue is one molecule, so the durability of growth rests on holding share and landing pipeline readouts. Second, competition: FcRn blockade is no longer argenx’s alone — J&J’s nipocalimab (approved 2025), UCB’s rozanolixizumab, and the complement and CD19 classes already compete in gMG, and Immunovant’s next-generation FcRn enters the picture in 2027. argenx’s defense is to compete on breadth and convenience (where it is genuinely ahead) rather than on the molecule (where the gap is closing).

On valuation, the ~$51B EV embeds the ~$13–14B consensus peak franchise being delivered; the stock is expensive versus mature biotech on absolute multiples but, growth-adjusted, screens as the cheapest name in its comp set and trades near its own historical median on price-to-sales. This memo takes no position and sets no price target; it lays out the embedded expectations, the scenarios, and the falsification tests on both sides.

2. Business Overview

What argenx does. argenx SE is a dual-listed (Euronext Brussels primary; Nasdaq ADS) immunology company founded in 2008 as a spin-out of Belgian and Dutch academic research, headquartered in Ghent (Belgium) and Amsterdam (Netherlands). It discovers and commercializes antibody therapeutics for severe autoimmune diseases. After a decade as a clinical-stage company funded by serial equity raises, it has become — on the strength of one product — a ~$4B-revenue, GAAP-profitable commercial enterprise with ~1,600 employees and a global commercial footprint across the US, Japan, Europe, and (via partner Zai Lab) Greater China.

The science and platform. Two engines underpin the company:

• The SIMPLE Antibody platform immunizes llamas and humanizes the resulting antibodies, exploiting the evolutionary distance between the camelid and human immune systems to surface novel epitopes that conventional human/mouse platforms miss. argenx layers Fc-engineering modules on top — most importantly ABDEG, the engineered Fc that converts efgartigimod into a high-affinity FcRn blocker.
• The Immunology Innovation Program (IIP) is a structured, “source-agnostic” model for translating novel immunology — drawn from academic collaborations and in-licensed biopharma assets — into clinical candidates. It is the origin of the broader pipeline (empasiprubart, adimanebart, and others) and the engine management points to for “at least one new pipeline candidate per year.”

Mechanism of the lead drug. Efgartigimod is a human IgG1-derived Fc fragment engineered to bind FcRn with high affinity. FcRn normally rescues circulating IgG from lysosomal degradation — the “recycling” mechanism that gives IgG its unusually long half-life. By out-competing endogenous IgG for FcRn, efgartigimod accelerates the breakdown of all IgG, including the pathogenic autoantibodies that drive diseases like gMG, CIDP and ITP, lowering total IgG by ~60–70%. Crucially it spares IgM/IgA and does not touch the complement cascade, giving it a clean, broadly applicable, infection-risk-favorable profile that is the foundation of the multi-indication strategy.

Formulations and the subcutaneous pivot. The franchise has three presentations, and the strategic story is the migration from infusion to self-injection:

• VYVGART — original intravenous efgartigimod (first gMG approvals 2021–2022).
• VYVGART Hytrulo (US) / VYVDURA (ex-US) — subcutaneous efgartigimod co-formulated with Halozyme’s ENHANZE (rHuPH20) hyaluronidase, enabling a ~30–90-second SC injection in place of a multi-hour IV infusion.
• A prefilled syringe (PFS) for self-injection launched in 2025 and, per management, was a primary driver of 2025 demand; a VYVGART SC autoinjector is guided for 2027 (an incremental, not step-change, convenience improvement aimed especially at needle-averse patients).

Revenue composition. FY2025 revenue of $4.15B is now essentially all product sales (collaboration/licensing revenue, which dominated the early years, is now immaterial; “other operating income” of ~$76M is mostly R&D tax incentives). The Q4 2025 regional split disclosed on the earnings call is instructive: US $1.10B, Japan $63M, rest-of-world $110M, and $26M of product supplied to Zai Lab for China — i.e., the US is ~85% of product sales, Japan a distant but meaningful second, Europe a price-constrained laggard, and China monetized via a royalty/transfer arrangement with Zai Lab (Zai books the China sales). The US net price in gMG is ~$225,000 per patient per year (management). Revenue is recurring in the economic sense that matters: these are chronic autoimmune diseases requiring ongoing cyclical dosing, so the installed base of ~19,000 patients is an annuity that compounds as new patients are added.

Verdict. A high-quality, high-margin, single-franchise commercial biotech with a genuinely differentiated platform and a clear, repeatable indication-expansion playbook — but with the corresponding fragility of deriving ~all revenue from one molecule.

3. Industry Dynamics

Where argenx sits. The company operates in rare/specialty autoimmune biologics — high-priced, physician-initiated biologic therapies for IgG-mediated autoimmune disease. The FcRn-antagonist class is a genuinely new modality, commercialized only since efgartigimod’s 2021 launch; it now sits alongside complement inhibitors and B-cell depleters as a competing mechanism across the same neurology and hematology indications.

Profit pool and structure. This is a structurally attractive corner of healthcare by the standard tests. Drugs are priced in the low-six-figures annually; gross margins run ~90%; populations are biomarker-defined and severe, which supports payer coverage; and the barriers to entry are steep. Using established competitive-strategy lenses (Greenwald’s barriers-to-entry framework and Marathon’s capital-cycle discipline), the industry exhibits: (1) a regulatory/clinical barrier — each indication requires its own multi-year, multi-hundred-million-dollar registrational program; (2) a rare-disease commercial barrier — finding and serving small, geographically dispersed patient populations requires a specialized salesforce and patient-services infrastructure that takes years and hundreds of millions to build (argenx now has >4,700 prescribers and a doubled US field footprint); and (3) biologic manufacturing complexity. Capital is gated by science, IP and the FDA — not by commodity competition — which keeps the capital cycle benign within each indication.

End-market sizing (US, the dominant market). The multi-indication thesis rests on a string of individually-modest but collectively-large rare-disease pools:

• gMG: ~82,700 US adults live with myasthenia gravis; argenx frames its addressable US gMG pool at ~60,000 once seronegative (+~11,000) and ocular (+~7,000) expansions are included. The anchor, proven market.
• CIDP: the single largest near-term lever — historically served by expensive IVIg; argenx’s initial addressable pool is the ~12,000 patients “not well managed” on current treatment, with a broader label permitting expansion beyond that. (Total US CIDP prevalence estimates range widely, into the tens of thousands.)
• ITP: ~20,000 newly diagnosed adults/year; approved in Japan, with the US registrational readout expected ~2027.
• The expansion universe: ocular MG, autoimmune myositis (IMNM ~20,000, no approved therapy), thyroid eye disease (program discontinued for futility, Dec 2025), Sjögren’s, Graves’ disease, pemphigus, membranous nephropathy and more — the “~15 indication” pipeline-in-a-product TAM that, if realized, is measured in the hundreds of thousands of US patients.

Reimbursement dynamics. These are ultra-orphan-to-rare biologics with strong payer leverage from severity, biomarker definition, and lack of alternatives — argenx reports >90% covered-lives access and ~20% gross-to-net. But as the class crowds (5+ branded options in gMG), payers gain negotiating power: step-edits against cheaper standard of care (steroids, IVIg, plasma exchange, rituximab) and increasingly against each other (formulary exclusivity, rebating). High gross margin today does not immunize the franchise from future net-price pressure as competition intensifies.

Verdict: structurally attractive at the class level, but crowding faster than most rare-disease markets at the flagship-indication level. The combination of high prices, ~90% gross margins, biomarker-defined populations and steep regulatory barriers makes this a genuinely good industry. The qualifier is real and worth stating plainly: gMG has gone from a one-drug market to a five-product battleground in roughly three years. High returns are visibly attracting capital into the FcRn niche — the classic early-stage warning sign in Marathon’s framework. The structural attractiveness is intact at the mechanism-class level but visibly eroding at the flagship-indication level, which is precisely why argenx’s strategy of running the indication count up faster than competitors can follow is the right — and necessary — response.

4. Competitive Position

The moat — named and pressure-tested. argenx’s advantage is best described in Greenwald’s taxonomy as a combination of demand-side/intangibles advantages (brand, physician relationships, clinical-data depth) plus early economies-of-scale-in-the-niche, reinforced by patent protection to ~2036. The honest framing — and the single most important analytical point in this memo — is that the durable part of the moat is the commercial/data/convenience lead, while the fragile part is the molecule’s mechanistic differentiation, because FcRn blockade is now a crowded mechanism. Calling the moat “FcRn leadership” overstates its durability; calling it “the scaled, broadest-label, only-fully-SC, data-richest franchise in the category” is accurate.

The competitive set (status mid-2026). The gMG battleground illustrates the crowding:

Pressure-testing each leg of the moat:

• “First and broadest” — real, but the most exposed leg. In gMG argenx is now one of six. Its May 2026 FDA expansion to all adult gMG (including seronegative) is the broadest label in the class and a direct answer to nipocalimab’s serotype limitation — but “broadest label” is a lead that competitors can chase with their own trials.
• Subcutaneous convenience — the strongest durable leg. The Hytrulo SC franchise, the PFS self-injection, and the 2027 autoinjector move efgartigimod toward true at-home self-administration. Of the FcRn peers only rozanolixizumab is SC; nipocalimab is IV. This is the hardest thing for a follower to leapfrog quickly and the clearest source of physician/patient stickiness.
• Switching costs — moderate, not high. A stable patient self-injecting at home, with a documented biomarker response and a patient-services wrap-around, is sticky — neurologists are reluctant to disrupt what works. But these are search/relationship switching costs, not contractual lock-in: a clearly superior or cheaper competitor can take share, and payers can force switches. Management’s own data point — six of ten biologic-naive MG starts choose VYVGART — is a statement about acquisition of new patients (where the lead is real), not about defense of the installed base against a future superior entrant.
• Clinical-data depth and breadth — real and compounding. The multi-indication dataset (gMG long-term OLE, CIDP ADHERE, ITP, ocular MG ADAPT-OCULUS, plus EULAR 2026 durability data in myositis/Sjögren’s) is a genuine intangible that funds label expansion faster than rivals can replicate. This is the leg most consistent with a durable advantage.
• IP / biosimilar cliff — better than the bear case implies. argenx’s composition-of-matter and ABDEG patents run to roughly 2036 in the US (~2034 ex-US), layered with formulation (ENHANZE SC) and method-of-use patents. Biosimilar efgartigimod is therefore a mid-2030s risk; the larger near-term threat is branded FcRn/complement/CD19 competition, not biosimilars. (The exact latest-expiring patent and any pediatric/PTE extensions warrant primary confirmation in the 20-F.)

Verdict: a real but narrowing lead — durable on convenience, breadth and data; most exposed in flagship gMG to J&J now and Immunovant later. argenx has a genuine moat, but it is not the mechanism. Its defense is to (a) win on SC convenience and the autoinjector, (b) hold the broadest-label high ground, and © out-run competition by widening the indication count faster than anyone can follow. That is competing on breadth, where it is genuinely ahead — not on molecule, where the gap is closing. An investor must underwrite management’s execution of that breadth strategy, because the molecule alone will not hold the fort indefinitely.

5. Growth History and Forward Opportunities

The historical ramp. Product net sales: ~$0.4B (2022) → $1.2B (2023) → $2.19B (2024) → $4.15B (2025, +90%), with Q1 2026 at ~$1.3B (+63% YoY) — the 17th consecutive quarter of growth. Total revenue stepped from $41M (2020) through a collaboration-revenue-distorted $497M/$411M (2021/2022) to the product-driven figures above. This is organic, single-product, ~89%-gross-margin growth, and it has been broadening in composition (gMG → CIDP, IV → SC, plus new label populations) rather than relying on price. By the highest-quality test — does the growth come from more customers buying a structurally advantaged product? — it passes cleanly.

The growth algorithm. Management runs a repeatable “indication-expansion playbook”:

1. gMG — the anchor, now with the broadest US label (all adult gMG, May 2026) and an ocular-MG sBLA to come (ADAPT-OCULUS hit its primary endpoint, p=0.012). Together these extend the addressable US pool toward ~60,000 patients. ~6 of 10 biologic-naive starts choose VYVGART; ~70% of patients switch up from oral therapies.
2. CIDP — the big near-term lever, ~18 months into launch; ~85% of patients switch from IVIg, with >90% covered lives and a recent UnitedHealthcare PFS win. Significant runway remains within the initial 12,000 “not-well-managed” pool, with early signs of expansion beyond it.
3. ITP — approved in Japan; US registrational readout ~2027.
4. The label-expansion machine — a cadence of registrational and proof-of-concept readouts: seronegative gMG (PDUFA May 10, 2026), ocular MG (filing pending), autoimmune myositis/IMNM (ALKIVIA Phase 3 readout ~H2 2026), Sjögren’s, Graves’ (two pivotal trials underway).

Vision 2030. The explicit targets: 50,000 patients treated, 10 labeled indications, and 5 pipeline candidates in Phase 3 by 2030. This is the quantified bull case and the standard against which execution should be judged.

The pipeline beyond efgartigimod (the diversification question). The single most important de-risking event would be a second commercial product. The candidates:

• Empasiprubart (ARGX-117) — an anti-C2 antibody blocking the classical and lectin complement pathways; the clearest “second pillar.” Phase 3 in multifocal motor neuropathy (MMN) and CIDP; the EMPASSION (MMN) topline is due ~Q4 2026 and is structured head-to-head against IVIg (a non-inferiority design with a pre-specified superiority test). MMN’s only approved therapy is IVIg, with progression in ~60% of patients — a clear unmet need.
• Adimanebart (ARGX-119) — a first-in-class MuSK agonist antibody that stabilizes the neuromuscular junction; entering Phase 3 in congenital myasthenic syndromes. (Its ALS Phase 2a failed — management does not read that across to CMS, where the biology is more direct.)
• Next-generation FcRn (ARGX-213, ARGX-124) — argenx’s own answer to the “cleaner FcRn” threat from Immunovant’s IMVT-1402, aimed at extending FcRn leadership “for decades.”
• Earlier IIP assets — ARGX-121 (anti-IgA), ARGX-118 (anti-Galectin-10), and out-licensed legacy assets (ARGX-115/ABBV-151 to AbbVie in oncology; ARGX-112 to LEO in dermatology; cusatuzumab).

Verdict: best-in-class growth — organic, durable, high-margin, now self-funding — but single-asset-concentrated and increasingly defended rather than uncontested. The +90%/+63% prints, the conversion to operating profitability, and the dense 2026–27 catalyst calendar make this a genuine compounder. The skeptical caveat is unavoidable: the growth algorithm depends on out-running competition by widening the indication count and the convenience gap, because the flagship gMG market is no longer argenx’s alone, and the second product (empasiprubart) remains pre-registrational. The quality of the growth is high; the durability of that growth is the live question.

6. Financial Quality

The inflection. FY2025 is the year the financial model turned. Selected figures (USD, IFRS):

* 2021 gross margin reflects collaboration-heavy revenue mix. ** FY2024 net income/EPS were inflated by a ~$725M one-time deferred-tax-asset recognition (see Quality of Earnings below); operating income that year was negative (~−$18M). FY2024 is not a clean earnings baseline.

Margins and operating leverage. Gross margin is ~89–91% and stable — a sole-source biologic with no meaningful COGS pressure. The operating-leverage story is the key chart: R&D + SG&A were ~150%+ of revenue in 2022 (when revenue was ~$0.4B) and fell to roughly 33% (R&D) + 33% (SG&A) of revenue in 2025 as the franchise scaled. Management has explicitly guided that revenue growth will exceed OpEx growth going forward, so operating margin should rise over time, while still investing heavily (most incremental OpEx into R&D to fund the pipeline). Incremental operating margin in 2025 was ~55% — the signature of a business with high fixed costs now scaling past breakeven.

Cash generation. FY2025 produced $685M of operating cash flow and $574M of FCF — the first positive year in the company’s history. Capex is modest and largely intangible (in-licensing/milestone payments of ~$106M) rather than physical plant; this is an asset-light, ~90%-gross-margin model. Note one quality nuance: 2025 operating cash flow ($685M) ran below net income ($1.29B), because rapid revenue growth tied up working capital (receivables grew ~$800M as sales scaled) — a benign, growth-driven divergence, not an earnings-quality red flag, but worth monitoring. SBC was $248M (a real, recurring, dilutive cost — ~$0.25 of every revenue dollar of OpEx).

Balance sheet. Pristine. Cash + short-term investments of $4.44B at 12/31/25, against only ~$47M of capital-lease obligations and no financial debt. Net cash funds the entire pipeline with no financing risk. Total equity is $7.32B; tangible book value per share is ~$115; cash/ST-investments per share is ~$72. (ROIC’s reported “book value per share” of −$4.44 and negative P/B are an IFRS share-premium/accumulated-deficit artifact, not a solvency signal — tangible book is solidly positive.) Net interest income of ~$159M in 2025 is a real earnings contributor from the cash pile.

Returns on capital. With the model just turning profitable, multi-year ROIC/ROE are not yet meaningful as a trend (they were deeply negative through 2023). FY2025 return on assets was ~17%; as the cash balance is partly excess, operating returns on the capital actually deployed in the franchise are far higher. The relevant statement is forward-looking: this is a ~90%-gross-margin, asset-light franchise whose returns on incremental capital are structurally very high — the question is durability, not level.

Verdict: economics improve dramatically with scale — the inflection is real and high-quality. A clean balance sheet, ~90% gross margins, demonstrated operating leverage, and first-year positive FCF. The two honest caveats: FY2024’s reported profit is a tax artifact (use FY2025 as the baseline), and SBC plus working-capital build mean cash earnings trail GAAP net income for now. Neither undermines the core conclusion that this is now a genuinely profitable, self-funding business.

7. Capital Allocation

The funding history. argenx was, until recently, a textbook serial-equity-funded R&D machine — and an unusually well-executed one. It raised fresh equity essentially every year from 2020–2023 to fund the pipeline:

The 2023 raise — ~$1.2B net, priced at $490/ADS — was the largest, and the pattern is the point: argenx raised into strength, at high and rising prices, minimizing dilution per dollar. Share count grew from 47.6M (2020) to 61.9M (2025), but the 2024–25 increase (~1.1M shares/year) is purely option/SBC dilution, not financing. Since FY2024 the company has raised no equity and now self-funds from VYVGART cash flow.

The reinvestment verdict. The strategy — raise dilutive equity at high prices, pour it into a single franchise and its label-expansion engine — worked, and is now validated by returns: the heavy R&D spend produced a $4.2B, +90%-growth franchise reaching ~19,000 patients. Capital allocation here earns an A grade on execution. There is no dividend and no buyback — the appropriate posture for a company still compounding revenue at >60% with a full pipeline to fund, and management has been explicit that capital goes to the pipeline.

Business development — a net out-licensor and royalty-payer, not an acquirer. argenx’s BD is asymmetric and disciplined: it has done essentially no M&A, instead in-licensing enabling technology and out-licensing non-core assets:

• Halozyme ENHANZE (2019) — argenx pays royalties for the SC delivery technology behind Hytrulo (the engine of its strongest moat leg).
• Zai Lab — Greater China efgartigimod partner; argenx received upfront (partly in Zai equity), cost-sharing and milestones, plus mid-teens royalties — making argenx a holder of Zai equity and a China royalty recipient rather than a direct China operator.
• AbbVie (ARGX-115/ABBV-151, oncology) and LEO Pharma (ARGX-112, dermatology) — out-licenses that fund the core without diluting focus.

Insider / Section-16 read. As a foreign private issuer, argenx is exempt from SEC Section 16, so there are no Form 3/4/5 filings in EDGAR — and that absence carries zero information. Any analysis inferring “no insider buying = no conviction” would be wrong here; insider transactions run through EU/Belgian/Dutch (FSMA/AFM, MAR/PDMR) disclosure rules not captured in the US corpus. (Any director/officer transactions near late-2025 highs would be disclosed under those EU rules; this is an open item worth a targeted AFM/FSMA pull, treated as unobserved, not absent.) Institutional ownership is high-quality at ~58%, led by Fidelity (~10–13%), T. Rowe Price and BlackRock — a sophisticated base that supports management but will not tolerate capital misallocation.

Verdict: management has allocated capital intelligently — A-grade execution, now de-risked. The serial high-priced raises funded a top-decile biotech outcome with minimal per-dollar dilution; the pivot to self-funding is demonstrated. The risk has shifted, not disappeared: with $4.4B of cash, no debt and growing FCF, the live question is deployment discipline — whether a newly cash-rich company resists value-destructive late-stage M&A or pipeline over-expansion. No capital-return framework has been articulated, which is fine today but becomes a live question as the IIP runway and growth rate normalize.

8. Changes and Headwinds — Last Two Years

Strategic and clinical milestones (positive):

• 2025 commercial execution: revenue +90% to $4.15B; first full-year operating profit (~$1.05B) and first positive FCF (+$574M); PFS self-injection launch; ~19,000 patients; >4,700 prescribers.
• Label expansion: positive seronegative gMG data and FDA approval expanding the gMG label to all adult patients (May 2026); positive ADAPT-OCULUS Phase 3 in ocular MG (p=0.012), sBLA to be filed; CIDP launch scaling with a UnitedHealthcare access win (>90% covered lives).
• Pipeline progress: empasiprubart Phase 3 (MMN/CIDP) advancing toward a Q4 2026 MMN readout; four new IIP molecules nominated in 2025; next-gen FcRn (ARGX-213/124) in/entering the clinic.

Governance change (neutral-to-watch): The most significant corporate change is the CEO transition. Announced 5 Jan 2026 and approved at the 6 May 2026 AGM: founder/CEO Tim Van Hauwermeiren moved to non-Executive Chairman, and COO Karen Massey became CEO. This is an internal, planned, telegraphed succession — Massey (COO since March 2023) ran the commercial machine that drove VYVGART to $4.2B, so it is continuity rather than a strategic break, and the founder remains on the board as Chair. The market reaction was a modest ~−5% on the announcement (a key-person-risk reaction, partially offset by the orderly structure). Also new: Sandrine Piret-Gerard as Chief Commercialization Officer. Management/incentive alignment is sound — remuneration is ~50%+ tied to financial-performance metrics and ~40% to innovation/pipeline milestones, with equity-heavy LTI.

Headwinds and setbacks (negative):

• Thyroid eye disease (TED) program discontinued for futility (Dec 2025) — a real crack in the “pipeline-in-a-product” thesis, demonstrating that the mechanism does not work in every IgG-mediated disease.
• ALS (adimanebart Phase 2a) failed — a high-risk indication, but another reminder of pipeline attrition.
• Intensifying competition: J&J’s nipocalimab approved (2025) and running a head-to-head trial; Amgen’s Uplizna approved in gMG (Dec 2025) with a twice-yearly dosing wedge; Immunovant’s next-gen FcRn advancing toward 2027 readouts.
• A brief FDA real-world-evidence review of CIDP worsening on switching from IVIg to VYVGART — since resolved with a label update reinforcing the ADHERE risk-benefit profile.

Verdict: the changes net to strengthening the near-term thesis (commercial inflection, label breadth, profitability) while raising the medium-term bar (competition, pipeline attrition, founder transition). Nothing here breaks the thesis; the TED failure and the competitive entries are the developments that most warrant ongoing monitoring.

9. Risk Analysis (Risk Matrix)

The risk profile is asymmetric in character: the probability of business impairment is low (profitable, net cash, durable IP, leading product), but the probability of share-price impairment on a single binary clinical/competitive event is meaningful, because the valuation leaves little margin of safety and the revenue base is concentrated in one molecule.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At ~$894/ADS the market cap is ~$55.3B and, net of $4.4B cash, EV is ~$50.9B. Against TTM (through Q1’26) revenue of $4.66B that is ~11x EV/sales; against FY2025 GAAP net income of $1.29B, ~45x trailing P/E (~38x on ~$23 consensus FY2026 EPS). These are rich absolute multiples — multiples of mature large-cap biotech (Regeneron ~3.9x sales/~14x earnings; Amgen ~5x/~14x; Vertex ~8x/~27x).

Growth-adjusted, the picture inverts. On an EV/sales-to-growth basis, ARGX (~11x ÷ ~70% growth ≈ 0.16) screens as the cheapest name in its comp set versus Vertex (~0.9), Regeneron (~1.3), and roughly in line with — or slightly cheaper than — its closest analog Alnylam (a single-platform, recently-profitable, ~80%-growth rare-disease name trading at ~12–14x sales). The premium to mature biotech is more than justified by growth + an 89% gross margin + the FCF inflection — if the growth is durable.

The own-history tell. On argenx’s own ~10-year price-to-sales range, the stock sits at only the 37th percentile — below its historical median — despite trading near an all-time-high price. The mechanism is simple and important: revenue has out-run the share price. This is the single most useful counter to a naive “it’s at all-time highs, it must be expensive” reaction. (P/E and P/B own-history percentiles are unavailable/meaningless here — distorted by the prior loss years and the IFRS book-equity artifact — so price-to-sales is the cleanest own-history gauge.)

Embedded expectations / reverse-DCF. The right question is what the ~$51B EV requires. A simple mature-state anchor: assume argenx matures into a Vertex/Regeneron-like ~22% net margin and trades at a normalized ~20x earnings. Justifying $51B EV then requires roughly $51B ÷ 20 ÷ 0.22 ≈ $11.6B of mature franchise revenue — which lines up almost exactly with the ~$11–14B sell-side consensus peak (ODDO ~$14B by 2035; Morningstar >$10B). Put differently, the market is paying ~3.7x the consensus peak, and the reverse-DCF says the price embeds that consensus peak being delivered — high-probability execution of the labeled and late-stage book (gMG, CIDP, seronegative/ocular expansions, and the leading pipeline indications). It is not paying for the speculative maximalist long tail (the full 10-indication Vision 2030, or a successful second molecule) — those are free options. Equally, it leaves essentially no premium and no margin of safety: the bar embedded is “operational consistency for another 6–8 years,” and a stumble re-rates the multiple, not just the estimates.

Scenario analysis (illustrative; not a price target). Undiscounted future franchise value, ~2032–34 horizon, on ~66M diluted ADS + ~$4.4B net cash:

*PV discounts the future value back ~6–7 years at ~9–10% (a factor of ~0.55–0.6). On that basis the base case roughly brackets today’s ~$894, the bull offers material upside, and the bear implies meaningful downside. The swing variables are mature operating margin (35% vs 48% nearly doubles equity value) and peak revenue (the bear’s $7B is not a disaster — it still assumes a multi-billion-dollar durable franchise that simply loses the “platform” multiple). The asymmetry skews positive only if one assigns >50% probability to base-or-better — which is precisely the variant-perception question.

11. Variant Perception

What consensus believes. ARGX is the FcRn category leader with a first-mover, sole-source biologic; the 17-quarter growth streak plus the May 2026 all-serotype gMG label and the CIDP launch make Vision 2030 credible; it is a quality-compounder you pay up for. Sell-side is overwhelmingly positive (consensus “Strong Buy,” average PT ~$1,009, ~+13% above spot).

The strongest bull case. A genuine pipeline-in-a-product. FcRn IgG reduction is mechanistically relevant across dozens of autoantibody diseases; each new Phase-3 read is a cheap call option because the platform, safety database, and commercial infrastructure are already paid for. At ~89% gross margin with FCF now positive, incremental indications drop straight to the bottom line. If even half of Vision 2030 lands, today’s ~11x sales is cheap in hindsight — and the own-history P/S at the 37th percentile says the stock is, against its own range, not expensive even at an all-time-high price.

The strongest bear case. ~100% single-asset concentration into a crowding class. J&J’s nipocalimab (approved 2025) is marketing head-to-head and leaning on a pregnancy-safety angle; UCB’s rozanolixizumab is established; Amgen’s Uplizna offers twice-yearly dosing; and Immunovant’s IMVT-1402 (next-gen, designed cleaner) reads out in gMG/Graves in 2027 and could leapfrog on convenience/tolerability. If FcRn becomes a price-competitive multi-player class before argenx monetizes the long tail, peak compresses toward the bear’s ~$7B, the platform multiple evaporates, and a $55B cap looks like ~8x a no-longer-hyper-growth single drug. A single marquee Phase-3 failure (TED already failed) would puncture the narrative the multiple rests on.

The 3–5 assumptions that matter most: (1) durability of FcRn share vs J&J/UCB/Amgen/Immunovant (drives peak: $7B vs $14B); (2) pipeline hit-rate on new indications (Vision 2030 needs multiple wins, not one); (3) mature operating margin (35% vs 48% swings equity value ~2x); (4) patent/biosimilar runway holding to ~2036; (5) the multiple’s glide path — does revenue compound faster than the platform premium fades?

Falsification tests. The bull breaks if: a marquee Phase-3 new-indication read fails, or Immunovant’s 2027 data shows clear superiority and starts taking share, or YoY growth decelerates below ~25% faster than expected. The bear breaks if: CIDP + seronegative gMG drive continued >50% growth through 2026–27 and a second indication (myositis/Sjögren’s) or empasiprubart confirms platform breadth, with margins inflecting toward 40%+.

Reconciling the tape with the fundamentals — the genuine variant tension. The factor/price read shows a strong, low-beta uptrend (+52% over twelve months, ~+27% over three) that has been consolidating near 52-week highs for ~6 months (roughly flat since the December-2025 ~$850–890 zone, within a ~$538–930 annual range). (Note: the FactorsToday leaderboard’s “+160% 3-month return / 4.75 Sharpe” are annualized figures — a ~+26% actual quarter (~$709→~$894, Mar→Jun) annualized to +160%, internally consistent with the feed’s other annualized horizons (m6 ~flat, y1 +52%), not a raw 3-month gain.) So this is not a parabolic momentum blow-off — it is a quality-biotech uptrend with a recent recovery leg, digesting a big run while fundamentals catch up. The reconciliation with the 37th-percentile own-history P/S is the key insight: the price ran, but revenue ran harder, so the stock is simultaneously near all-time-high price and below its own historical sales multiple. The de-rating risk here is therefore a binary clinical/competitive event, not the unwinding of an obviously irrational multiple. That is why the binary-event calendar (myositis H2’26, empasiprubart Q4’26, Immunovant 2027) and position sizing matter more than the headline P/E.

12. Fact vs. Interpretation Table

13. Open Questions

1. What does the J&J EPIC head-to-head (nipocalimab vs VYVGART) show, and when does it read out? A direct comparative loss would be the single most damaging competitive event.
2. Immunovant IMVT-1402 2027 gMG/Graves data — does the “cleaner FcRn” deliver a convenience/tolerability edge that takes share?
3. Exact latest-expiring efgartigimod patents (Orange/Purple Book) and any pediatric/PTE extensions — confirm the ~2036 figure in the 20-F.
4. Geographic revenue economics — argenx discloses regional product sales only intermittently; the durable US/Japan/EU margin mix and the Zai China royalty magnitude are under-disclosed.
5. EU MAR/PDMR insider transactions — were there director/officer sales near late-2025 highs? Not captured in EDGAR; requires AFM/FSMA pull. Treat as unobserved.
6. Mature operating margin — will argenx let margins inflect toward 45%+, or keep reinvesting at a level that holds them in the mid-30s? The single biggest valuation swing factor.
7. Capital-return framework — at what point (and how) does a cash-rich, decelerating-growth argenx return capital?
8. CIDP expansion beyond the initial 12,000 — is the early “beyond IVIg-switchers” trend real and sizable?

14. What Must Be True

For the bull case to be right (and its falsification test):

• Must be true: argenx holds the majority of new FcRn/biologic starts in gMG and converts CIDP, ocular/seronegative MG, and at least two of {myositis, Sjögren’s, ITP, Graves’} into approved, commercially-meaningful indications — driving the franchise toward $11B+ — while empasiprubart (or a next-gen FcRn) becomes a genuine second product, and operating margins inflect toward 40%+.
• Falsification test: Year-on-year growth decelerates below ~25% earlier than the labeled-indication ramp implies, or a marquee Phase-3 (myositis H2’26 / empasiprubart MMN Q4’26 / Graves’) fails, or Immunovant’s 2027 data demonstrably takes share. Any one materially weakens the “platform compounding” thesis on which the multiple rests.

For the bear case to be right (and its falsification test):

• Must be true: FcRn/complement/CD19 competition (J&J, UCB, Amgen, Immunovant) caps argenx’s share and compresses net price, the pipeline delivers more disappointments (after TED and ALS), and the franchise plateaus around $7B as a one-product, no-longer-hyper-growth biologic — at which point the platform premium collapses and the stock de-rates toward a mature-biotech multiple.
• Falsification test: CIDP + seronegative/ocular gMG sustain >50% franchise growth through 2026–27 and a clean second-indication win (myositis or empasiprubart MMN) confirms platform breadth, with operating margin inflecting toward 40%+ — demonstrating the growth is durable and diversifying, not a single-molecule peak.

The investment debate reduces to a single question: is efgartigimod a durable, expanding platform, or a magnificent single product approaching a competitively-contested peak? The price requires the former with high confidence and pays little for being wrong.

15. Source Appendix

The full citation list follows below in the Source Appendix. Primary sources include: argenx SE FY2025 results and 20-F (filed 2026-03-19, CIK 0001697862); Q4 2025 earnings-call transcript (2026-02-26, via ROIC.ai); Q1 2026 results (2026-05-07); FDA approval announcements (all-adult gMG, May 2026); ADAPT-OCULUS topline (Feb 2026); EULAR 2026 data (Jun 2026); ROIC.ai financial data; AZI valuation/news feeds; FactorsToday factor data (leaderboard returns are annualized — the m3 “+160%” is the ~+26% quarter annualized, reconciled to the price CSV); and competitor filings/approvals (J&J nipocalimab, UCB rozanolixizumab/zilucoplan, Amgen inebilizumab, Immunovant IMVT-1402).

The body of this article takes no investment position and contains no price target; the sole exception is the labeled “Claude’s Take” opening block, which is the author’s own independent opinion.

APPENDIX A — Standard Diligence Questionnaire

argenx SE (NASDAQ: ARGX) | As-of 2026-06-14

Supplemental to the main article. Fact / Interpretation / Assumption labels applied where it matters. Where a question does not map to a commercial-stage single-product biotech, the correct analog is given.

General

What thoughtful questions have other investors asked about this company? The sell-side and buy-side debate clusters on five points, all surfaced on recent earnings calls: (1) competition — confidence in the VYVGART profile against newly-approved nipocalimab (J&J) and the head-to-head EPIC trial (asked by Goldman, Barclays); (2) net price durability across the new sub-indications (seronegative ~$225k, ocular) and as the class crowds (BofA, Citi); (3) CIDP expansion beyond the initial 12,000 “not-well-managed” patients toward frontline use (Truist, Wells Fargo); (4) the founder-to-Massey CEO transition rationale and timing (TD Cowen, Morgan Stanley); and (5) operating-margin trajectory / OpEx growth now that the company is profitable (William Blair, Barclays). The deepest structural question is whether efgartigimod is a durable expanding platform or a magnificent single product nearing a contested peak.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither cyclical-high nor -low — argenx is in the early innings of a secular ramp, not a cycle. FY2025 ($1.29B net income) is the first profitable year; earnings are inflecting upward from a loss base, driven by internal commercial execution and operating leverage, not by an external cycle. (Fact)

Driven by the external environment or internal actions? Overwhelmingly internal — product launches, label expansions, the PFS self-injection rollout, and operating leverage. The business is largely insensitive to macro/economic cycles (rare-disease biologics are non-discretionary, reimbursed). The relevant external variables are competitive entry and payer policy, not GDP. (Interpretation)

How stable are revenues? Highly stable and recurring in the economic sense: chronic autoimmune diseases require ongoing cyclical dosing, so the ~19,000-patient installed base is an annuity. Quarterly seasonality exists (Q1 softness from re-verifications and winter storms, per management). Concentration in one molecule is the stability risk, not demand volatility. (Fact/Interpretation)

Outlook for products/services? Strong near-term: +63% Q1’26 growth, broadest gMG label, scaling CIDP launch, and a dense 2026–27 catalyst calendar (seronegative PDUFA, ocular sBLA, myositis Phase 3, empasiprubart MMN). (Fact)

How big will this market be — growing, shrinking, domestic or international? Growing. The targeted IgG-mediated autoimmune universe spans ~15 indications and hundreds of thousands of US patients if Vision 2030 is realized; today the franchise serves ~19,000. Primarily a US profit pool (~85% of sales), with Japan #2, Europe price-constrained, and China monetized via Zai Lab royalties. (Fact/Assumption on the 15-indication TAM)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More. gMG went from a one-drug market to a 5–6 product battleground in ~3 years (efgartigimod, nipocalimab, rozanolixizumab, zilucoplan, ravulizumab, inebilizumab), with Immunovant’s next-gen FcRn arriving ~2027. (Fact)

How profitable is the business (ROIC, ROE)? Just turned profitable; FY2025 ROA ~17%, operating margin ~25% (rising), gross margin ~89%. Multi-year ROIC/ROE are not yet a meaningful trend (negative through 2023). Returns on incremental capital deployed in the franchise are structurally very high given the ~90% gross margin and asset-light model. (Fact)

How profitable is the industry — competitors, barriers to entry? Very profitable (rare-disease biologics, ~90% gross margins). Barriers are high: multi-year registrational trials per indication, specialized rare-disease commercial infrastructure, biologic manufacturing, and IP. But within the flagship gMG indication, returns are visibly attracting capital (the early-cycle warning). (Interpretation)

Can the business be easily understood? Reasonably — one mechanism (FcRn-mediated IgG reduction), one lead molecule, a clear indication-expansion playbook. The complexity is in the clinical/regulatory probabilities across ~15 indications and the competitive dynamics. (Interpretation)

Can it be undermined by foreign low-cost labor? No. The product is a patent- and FDA-protected biologic; the threat is branded innovation and (post-2036) biosimilars, not low-cost labor. (Fact)

Do brands matter? Yes, in the physician/prescriber sense — VYVGART is the #1-prescribed MG biologic, capturing 6 of 10 biologic-naive starts; that brand/relationship equity with neurologists is a genuine intangible asset and the basis for cross-indication pull-through. (Fact/Interpretation)

What is the nature of competition? Clinical differentiation (efficacy, safety, label breadth), convenience (SC self-injection vs IV), and increasingly payer access/price. argenx competes on breadth and convenience, where it leads, rather than on the molecule, where the gap is closing. (Interpretation)

Customers’ switching costs? Moderate. A stable, home-self-injecting patient with a documented response is sticky (neurologists avoid disrupting what works), but these are relationship/search switching costs, not contractual lock-in — a clearly superior or cheaper entrant can take share, and payers can force switches. (Interpretation)

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the most valuable asset, the efgartigimod franchise IP and platform, is largely internally generated and not capitalized at fair value. Tangible book (~$115/sh) vastly understates economic value. (Interpretation)

Off-balance-sheet liabilities? None material identified — royalty obligations to Halozyme (ENHANZE) and milestone/royalty commitments are contractual but contingent; ~$47M of capital leases on-balance-sheet. No debt, no pension, no securitizations. (Fact)

How conservative is the accounting? Reasonably conservative under IFRS; the principal nuance is the FY2024 ~$725M one-time deferred-tax-asset recognition that inflated reported net income — a non-cash, non-recurring item that must be normalized out (operating income was negative that year). The IFRS treatment also produces a negative reported book equity per ROIC (a share-premium/accumulated-deficit artifact), not a solvency issue. (Fact)

How CapEx-hungry is the business? Very light on physical capex (~$6M of fixed-asset purchases in 2025); the larger “capex” line is intangible in-licensing/milestone payments (~$106M). Asset-light, ~90%-gross-margin model. (Fact)

Capital Allocation & Management

How much FCF does the business generate, and how is it used? FY2025 FCF +$574M (first positive year). It is retained and reinvested into the pipeline and commercial expansion; no dividend, no buyback. Cash balance grew >$1B in 2025 to $4.4B. (Fact)

Capital-allocation philosophy? Reinvest everything into the pipeline-in-a-product and the IIP; fund via internally-generated cash (since FY2024) after a well-executed phase of high-priced equity raises (2020–2023, ~$3.9B, into strength). No M&A. (Fact/Interpretation)

Significant acquisitions recently? None — argenx is a net out-licensor (AbbVie, LEO) and technology in-licensor (Halozyme ENHANZE; Zai Lab China partnership), not an acquirer. (Fact)

Buying back shares? No. (Fact)

Issuing large amounts of new shares to insiders? SBC is $248M/yr (~1.1M net new shares/yr from options/RSUs; ~4M diluted overhang, ~6.6%). Material and recurring, but incentive-aligned (equity-heavy LTI). Historical share growth (47.6M→61.9M, 2020–25) was mostly financing raises, now ended. (Fact)

Compensation policy of directors/management? Heavily performance- and pipeline-weighted: ≥50% of STI tied to financial-performance metrics, ≥40% to innovation/pipeline milestones; LTI ≥50% performance-based and equity-heavy. Well-aligned with the actual value drivers. (Fact)

Motivations of management? Founder-led culture (Tim Van Hauwermeiren, now Chair) with a patient-centric, science-driven mission; internal succession to Karen Massey (ex-COO) signals continuity. Incentives favor sustained commercial growth + pipeline advancement. Credibility is high (top-decile biotech outcome built from a 2008 spin-out). (Interpretation)

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? It is an ADR/ADS (Nasdaq, 1:1 with the ordinary share; primary listing Euronext Brussels). Foreign private issuer filing 20-F + 6-K — not an MLP or K-1 issuer. US holders should note FPI status (no Section-16 insider data; potential foreign-tax/withholding considerations on any future distributions). (Fact)

Dividend policy? No dividend; none expected near-term (reinvestment phase). (Fact)

How profitable is the business? ~89% gross margin, ~25% operating margin (rising), ~31% net margin in FY2025 (flattered by tax). Structurally high-margin. (Fact)

Is net income diverging from cash from operations? Yes, currently — FY2025 OCF ($685M) ran below net income ($1.29B), because rapid revenue growth tied up working capital (receivables +~$800M) and net income included non-cash tax/interest items. This is a benign, growth-driven divergence to monitor, not an earnings-quality red flag. (Fact/Interpretation)

Risks & Downside

What factors would cause the stock to decline? A competitive loss (J&J EPIC head-to-head; Immunovant 2027 data showing superiority); a marquee Phase-3 failure (myositis, Graves’, empasiprubart MMN); a growth deceleration below expectations; net-price/reimbursement pressure as the class crowds; or a general biotech/multiple de-rating. Given the rich valuation, any of these re-rates the multiple sharply. (Interpretation)

Risk of a catastrophic loss? Low at the business level — profitable, $4.4B net cash, durable IP, leading product, diversified payer base. The realistic catastrophic scenario is a black-swan drug-safety signal on efgartigimod (given single-asset concentration). (Interpretation)

Chance of a total loss? Very low. A profitable, net-cash, IP-protected franchise does not go to zero absent an extreme safety event. (Interpretation)

Recent News & Events

Has the business environment changed recently? Yes, on two fronts: (1) commercial inflection — first full-year profitability, all-adult gMG label (May 2026), positive ADAPT-OCULUS, scaling CIDP; and (2) intensifying competition — J&J nipocalimab approved (2025) and running a head-to-head trial, Amgen Uplizna approved in gMG (Dec 2025), Immunovant’s next-gen FcRn advancing toward 2027. Also the TED program was discontinued (Dec 2025) and the ALS Phase 2a failed. (Fact)

Significant acquisitions? None. (Fact)

Change in accounting policies? None material; the FY2024 one-time deferred-tax recognition is the key distorting item to normalize. (Fact)

Recent changes — new markets, facilities, management? Major management change: founder Tim Van Hauwermeiren → Chairman; Karen Massey (ex-COO) → CEO (announced Jan 2026, AGM-approved May 2026); new Chief Commercialization Officer Sandrine Piret-Gerard. Continued geographic/indication expansion; PFS self-injection launch; autoinjector planned 2027; a new China research affiliate (distinct from the Zai commercial license). (Fact)

APPENDIX B — Source Appendix

argenx SE (NASDAQ: ARGX) | As-of 2026-06-14

Sources prioritized primary-first. All URLs accessed 2026-06-14 unless noted. Third-party aggregated data (ROIC.ai, AZI, FactorsToday) reconciled to filings where material; management commentary treated as hypothesis and validated against filings/financials/external evidence per the research framework.

Primary — Company filings & disclosures

• argenx SE Form 20-F (FY2025) — filed 2026-03-19, CIK 0001697862. https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm (incl. remuneration policy exhibit). Mirrored locally to output/ARGX/sources/.
• argenx FY2025 full-year results & Q4 business update — 2026-02-26. https://www.globenewswire.com/news-release/2026/02/26/3245199/0/en/argenx-Reports-Full-Year-2025-Financial-Results-and-Provides-Fourth-Quarter-Business-Update.html
• Q4 2025 earnings-call transcript — 2026-02-26, via ROIC.ai (get_earnings_call_transcript). Regional revenue split, ~$225k net gMG price, 19,000 patients, ADAPT-OCULUS p=0.012, OpEx/tax guidance, CEO-transition commentary.
• argenx Q1 2026 results — 2026-05-07. https://argenx.com/news/2026/press-release-3289577
• FDA approval — VYVGART/VYVGART Hytrulo for all adult gMG (incl. seronegative) — 2026-05-08. https://www.globenewswire.com/news-release/2026/05/08/3291372/0/en/argenx-announces-u-s-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use-in-all-adult-patients-living-with-gmg.html
• argenx — AGM results & appointment of Karen Massey as CEO — 2026-05-06. https://www.globenewswire.com/news-release/2026/05/06/3289289/0/en/argenx-Announces-Results-of-Annual-General-Meeting-and-Board-of-Directors-Appointment-of-Karen-Massey-as-Chief-Executive-Officer.html
• argenx — CEO transition announced — 2026-01-05. https://www.statnews.com/2026/01/05/argenx-ceo-to-step-down-tim-van-hauwermeiren-karen-massey/
• argenx 2026 Strategic Priorities (Vision 2030 targets) — 2026-01-12. https://www.globenewswire.com/news-release/2026/01/12/3216531/0/en/argenx-Highlights-2026-Strategic-Priorities.html
• EULAR 2026 — long-term efgartigimod data in myositis & Sjögren’s — 2026-06-03. https://www.globenewswire.com/news-release/2026/06/03/3305765/0/en/argenx-Presents-New-Efgartigimod-Data-Showing-Long-Term-Sustained-Patient-Benefit-in-Myositis-and-Sjogren-s-Disease-at-EULAR-2026.html
• argenx Annual Report — Intellectual Property section (patent-expiry framing ~2034–2036). https://reports.argenx.com/2023/argenx-group/intellectual-property.html

Primary — Partnership / BD source documents

• argenx–Halozyme ENHANZE collaboration — 2019-02-04. https://www.globenewswire.com/news-release/2019/02/04/1709517/0/en/argenx-and-Halozyme-enter-global-collaboration-and-license-agreement-for-ENHANZE-technology.html
• Zai Lab efgartigimod Greater-China license (Zai Lab 8-K exhibit). https://www.sec.gov/Archives/edgar/data/0001704292/000119312521003104/d70511dex991.htm
• AbbVie–argenx ARGX-115 (ABBV-151) collaboration — 2016-04-21. https://news.abbvie.com/2016-04-21-AbbVie-and-argenx-to-Collaborate-on-ARGX-115-Against-Novel-Immuno-Oncology-Target
• LEO Pharma–argenx ARGX-112 collaboration — FierceBiotech. https://www.fiercebiotech.com/partnering/argen-x-pairs-up-leo-pharma-a-116m-dermatology-deal

Primary — Competitor approvals / status

• J&J nipocalimab (Imaavy) FDA approval (gMG) — 2025-04-30. https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-approval-for-imaavytm-nipocalimab-aahu
• AstraZeneca/Alexion ravulizumab (Ultomiris) gMG approval — NeurologyLive. https://www.neurologylive.com/view/fda-approves-ravulizumab-adults-with-generalized-myasthenia-gravis
• Immunovant IMVT-1402 status (next-gen FcRn; batoclimab discontinuation) — FierceBiotech / myastheniagravisnews. https://www.fiercebiotech.com/biotech/immunovant-shunts-next-gen-fcrn-drug-ahead-batoclimab-race-rival-vyvgart ; https://myastheniagravisnews.com/news/phase-3-trial-imvt-1402-mg-advancing-with-march-goal/
• UCB Rystiggo (rozanolixizumab) and Zilbrysq (zilucoplan); Amgen Uplizna (inebilizumab) gMG approval (Dec 2025) — company/FDA approval records.

Secondary — Epidemiology & industry

• Myasthenia gravis US epidemiology — PMC12186037 (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12186037/
• CIDP prevalence / claims analysis — Karger (2024). https://karger.com/ned/article/doi/10.1159/000550418/942820/
• ITP epidemiology — StatPearls/NCBI. https://www.ncbi.nlm.nih.gov/books/NBK562282/
• FcRn-inhibitor mechanism review — PMC12371811 (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12371811/

Quantitative data feeds (third-party; reconciled to filings)

• ROIC.ai MCP — income statement, balance sheet, cash flow, profitability ratios, enterprise value, valuation multiples, per-share data, earnings-call transcripts. Primary quantitative source for FY2020–2025 financials and ratios.
• AZI feeds (azi.sh) — news (3 important items; foreign-issuer feed sparse) and valuation_index own-history percentiles (P/S 37th percentile; P/E & P/B unavailable). Price history CSV (OHLCV + EMAs/beta) — used to verify the price/momentum read.
• FactorsToday API — factor loadings (Country Belgium 1.24, Industry Biotech 0.81, Market 0.69; R²~0.33), leaderboard (returns annualized: y1 +52%, y3 +31.7% ann., y5 +27.3% ann., max DD −38%; the m3 “+160% / 4.75 Sharpe” are the latest quarter’s ~+26% move annualized — internally consistent with the other horizons, not an anomaly), related-stocks (REGN, AMGN, ASND relevant; WAT/MTD/A/TEL life-science-tools by quality/low-vol similarity).
• Sell-side consensus / PTs — stockanalysis.com/ARGX (FY26E rev ~$5.1B, EPS ~$23; FY27E ~$6.2B); Morningstar peak-sales note (>$10B; ODDO ~$14B by 2035); Wedbush PT $1,000 (2026-06-11); consensus avg PT ~$1,009.
• Peer comps — stockanalysis.com / company filings for Vertex (VRTX), Regeneron (REGN), Amgen (AMGN), Alnylam (ALNY), Immunovant (IMVT).

Note on momentum data: the FactorsToday leaderboard returns are annualized at every horizon — the m3 “+160% / 4.75 Sharpe” is the latest quarter’s ~+26% actual move (~$709→~$894, Mar→Jun 2026) expressed on an annualized basis, reconciled against the AZI daily price CSV and consistent with the other horizons (m6 ~flat, y1 +52%). The verified read used throughout: a strong ~+52% twelve-month uptrend with a recent recovery leg, near 52-week highs within a ~$538–930 range.